sglt2 inhibitors vs glp-1 Disparities in Inhibitor or Glucagon-Like Peptide 1 Receptor Agonist Initiation Among Medicare-Insured Adults With CKD in the United States GLP-1 Receptor Agonist Therapy With

Potential Downsides of Microdosing Reduced Efficacy One of the primary concerns with microdosing GLP-1 drugs is that lower doses may not provide the desired therapeutic effects

These are typically mild and temporary, but patients should report any persistent discomfort to their healthcare provider

Although Ozempic, Mounjaro, and Rybelsus are not FDA-approved for obesity treatment, they are included in the analysis due to the high number of patients with an obesity diagnosis using these products compared to other FDA-approved Type 2 diabetes GLP-1 agonists

97 When assessing seizure and epilepsy separately, newer agents significantly lowered the risk of seizure (RR = 0.78, 95% CI: 0.601.00

In all clinical trials, participants who lost the most weight paired medication with intensive diet and exercise modifications

Strategic Expansion GLP-1 has fueled a two-speed deal environment, with different buyers pursuing fundamentally different strategies